BOSTON – Jan. 9, 2019 – For the fifth consecutive year, Greenberg Traurig, LLP’s global Life Sciences & Medical Technology Group hosted two events coincident with the JP Morgan Healthcare Conference in San Francisco.
On Jan. 7, 2019, from 11:30 a.m.–2 p.m., the Group presented a lunchtime Deal-Making Trends panel discussion where seasoned executives from leading life sciences companies shared insider views on current deal trends, best practices, and pitfalls, including M&A, licensing, joint ventures, and strategic collaborations. They also shared predictions on what 2019 will hold for deal-making. Panelists from the United States, Europe, and China included:
- Shaun Grady, VP Strategic Partnering and Business Development, AstraZeneca
- Jeremy Sohn, VP, Head of Digital Business Development & Licensing; Global Head of Digital Development, Novartis
- Qingxi (Charles) Wang, President, International Division, CSPC Pharmaceutical Group
- Fiona Adams, co-chair of Greenberg Traurig Global Corporate Practice and co-managing shareholder of the firm’s London office
- Lori G. Cohen, co-chair of Greenberg Traurig’s Global Litigation Practice, chair of the firm's Trial Practice Group, chair of the Pharmaceutical, Medical Device & Health Care Litigation Practice, and co-chair of the Atlanta Litigation Practice
The panel was moderated by the co-chairs of Greenberg Traurig’s global Life Sciences & Medical Technology Group, David J. Dykeman (Boston shareholder, patent attorney and co-chair of Boston Intellectual Property & Technology Group) and David C. Peck (Fort Lauderdale shareholder, Corporate & Securities).
The program was followed that evening by a private wine tasting and networking reception attended by more than 300 healthcare industry executives and investors.
In addition, Greenberg Traurig participated in three other events coincident with the JP Morgan Healthcare Conference. The firm sponsored the Virginia Bio reception as well as a breakfast with undefeated IBF-USBA Light Heavyweight champion, Mike Lee, hosted by FocalPoint Partners. Boston Corporate shareholder Gregory R. Daddario and Washington, D.C. Corporate shareholder Trevor Chaplick also introduced companies at the Biotech Showcase Conference.
About Greenberg Traurig’s Life Sciences & Medical Technology Group:
Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing. As part of the group, the Biotechnology and Pharmaceutical Industry Group focuses on advising clients in the biotechnology and pharmaceutical sectors.
About Greenberg Traurig
Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2018 Am Law Global 100. Web: www.gtlaw.com; Twitter: @GT_Law.